Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9530757 | PMC |
| http://dx.doi.org/10.1148/rycan.220121 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Diagnostic Performance of O-RADS US (Version 2019 and Version 2022) Incorporating Acoustic Shadowing by Junior Radiologists: Analyzing 1061 Adnexal Masses.
J Ultrasound Med
January 2025
Department of Ultrasonic Medicine, Fetal Medical Centre, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
Introduction: Acoustic shadowing is an important benign ultrasound (US) feature for adnexal masses (AMs). To validate the diagnostic performance and interobserver agreement of the 2019 version and 2022 version of Ovarian-Adnexal Reporting and Data System Ultrasound (O-RADS US) and ascertain whether adding acoustic shadowing to O-RADS US v2019 as a benign ultrasound feature can enhance its diagnostic efficacy among junior radiologist.
Methods: This retrospective study included consecutive women with suspected adnexal masses who underwent ultrasound examinations between September 2022 and January 2024.
Implementation of O-RADS Ultrasound Reporting System: A Quality Improvement Initiative.
Can Assoc Radiol J
January 2025
Department of Medical Imaging, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.
To determine the feasibility of implementing Ovarian-Adnexal Reporting & Data System (O-RADS) ultrasound (US) for reporting of adnexal masses at our institution, with a specific goal of increasing the use of O-RADS from a baseline of <5% to at least 75% over a 16-month period. A prospective interrupted time series quality improvement study was undertaken over a 16-month period. Plan, do, study, act cycles included: (1) Engagement of interested parties, (2) Targeted educational sessions, (3) Development of reporting templates, (4) Weekly audit-feedback.
View Article and Find Full Text PDFDiagnostic Value of the Ovarian-Adnexal Reporting and Data System Ultrasound in Ovarian Masses: A Two-Center Study.
Br J Radiol
December 2024
Ultrasound Department, Fourth Affifiliated Hospital of Harbin Medical University, Surgeon's Hall, No. 37, Yiyuan Road, Nangang District, Harbin City, Heilongjiang prov, China.
Objective: This study aimed to assess the diagnostic efficacy of the Ovarian-Adnexal Reporting and Data System (O-RADS) and Ultrasound (US) and its sub-classification system for distinguishing ovarian masses.
Methods: O-RADS US was used for the retrospective analysis of 606 ovarian masses of Chinese from two medical centers by two gynecologic sonographers with varying experience. The O-RADS 4 categories masses were further sub-classified into O-RADS 4a and O-RADS 4 b through three different approaches(O-RADS A1/A2/A3).
Ovarian-Adnexal Imaging-Reporting and Data System (O-RADS) ultrasound version 2019: a prospective validation and comparison to updated version (v2022) in pathologically confirmed adnexal masses.
Eur Radiol
November 2024
Department of Diagnostic Radiology, Faculty of Human Medicine, Zagazig University, Zagazig, Egypt.
Objective: To evaluate the diagnostic accuracy and reliability of the Ovarian-Adnexal Reporting and Data System (O-RADS) ultrasound v2019 in classifying adnexal masses (AMs) and compare the old and updated systems (v2022).
Patients And Methods: This prospective study enrolled 977 consecutive women with suspected AMs from three institutions between January 2022 and December 2023. Ultrasound examinations were performed by three experienced radiologists who categorized AMs according to O-RADS ultrasound v2019.
The predictive value of nomogram for adnexal cystic-solid masses based on O-RADS US, clinical and laboratory indicators.
BMC Med Imaging
November 2024
Department of Ultrasound, Shenzhen Second People's Hospital, The First Affiliated Hospital of Shenzhen University Health Science Center, No.3002, Sungang West Road, Futian District, Shenzhen, China.
Background: Ovarian cancer remains a leading cause of death among women, largely due to its asymptomatic early stages and high mortality when diagnosed late. Early detection significantly improves survival rates, and the Ovarian-Adnexal Reporting and Data System Ultrasound (O-RADS US) is currently the most commonly used method, but has limitations in specificity and accuracy. While O-RADS US has standardized reporting, its sensitivity can lead to the misdiagnosis of benign masses as malignant, resulting in overtreatment.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!